<DOC>
	<DOC>NCT00132418</DOC>
	<brief_summary>The objective of this study was to evaluate the safety of Enbrel (etanercept) in rheumatoid arthritis (RA) subjects with greater than or equal to 1 documented comorbid disease (diabetes mellitus; chronic pulmonary disease; pneumonia within the last year; or recurrent bronchitis, sinusitis, or urinary tract infection) that might increase infection risk.</brief_summary>
	<brief_title>Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Active RA Documented comorbid condition (diabetes mellitus requiring insulin or oral hypoglycemic agents; chronic pulmonary disease; history of pneumonia in the last year; or recurrent bronchitis, sinusitis or urinary tract infection) Able to selfinject study drug Previous use of antitumor necrosis factor (TNF) monoclonal antibody Receipt of antiCD4 or diphtheria interleukin2 fusion protein within the previous 6 months with subsequent abnormal absolute T cell count Receipt of intraarticular corticosteroids within 2 weeks before screening Receipt of cyclosporine, thalidomide or azathioprine within 4 weeks before screening Significant concurrent medical diseases (serious infection; open cutaneous ulcers; current antibiotic treatment; myocardial infarction [MI] within 12 months of screening; angina pectoris; uncontrolled hypertension; cancer; or HIV positive)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>rheumatoid arthritis and at least 1 qualifying comorbid condition (diabetes, chronic pulmonary disease, recent infection)</keyword>
	<keyword>RA</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>